Physician profile
Michael Lebowitz
NPI 1811090749
$7,477.12
in general payments reported to CMS, 2019-2025
24 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $1,287 · 2021: $1,352 · 2022: $1,297 · 2023: $834 · 2024: $619 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.66 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,368.52 | 2019-2022 | |
| Allergan, INC. | $1,071.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $703.20 | 2019-2024 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $405.08 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $367.87 | 2019-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $303.54 | 2019-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $229.25 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $217.47 | 2019-2024 | Austedo, Austedo Xr, Uzedy |
| Lundbeck LLC | $176.44 | 2019-2023 | Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $155.11 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $123.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $112.95 | 2019-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $86.53 | 2019-2024 | Ingrezza |
| Indivior INC. | $74.30 | 2019-2023 | Perseris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.14 | 2021-2022 | |
| Shire North American Group INC | $48.90 | 2019 | |
| Axsome Therapeutics, INC. | $39.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.53 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $30.87 | 2020 | |
| Tris Pharma INC | $29.77 | 2023-2024 | Dyanavel Xr |
| Bioxcel Therapeutics, INC. | $25.06 | 2023 | Igalmi |
| Boston Scientific Corporation | $24.31 | 2021 | |
| Eisai INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.